Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Current Deferred Revenue (2023 - 2024)

Historic Current Deferred Revenue for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Q2 2025 value amounting to $138252.7.

  • Zhengye Biotechnology Holding's Current Deferred Revenue changed N/A to $138252.7 in Q2 2025 from the same period last year, while for Jun 2025 it was $138252.7, marking a year-over-year change of. This contributed to the annual value of $477000.0 for FY2024, which is 2673.4% down from last year.
  • As of Q2 2025, Zhengye Biotechnology Holding's Current Deferred Revenue stood at $138252.7.
  • Zhengye Biotechnology Holding's 5-year Current Deferred Revenue high stood at $639020.9 for Q4 2023, and its period low was $27843.1 during Q4 2024.
  • For the 3-year period, Zhengye Biotechnology Holding's Current Deferred Revenue averaged around $268372.3, with its median value being $138252.7 (2025).
  • Within the past 5 years, the most significant YoY rise in Zhengye Biotechnology Holding's Current Deferred Revenue was 9564.28% (2024), while the steepest drop was 9564.28% (2024).
  • Zhengye Biotechnology Holding's Current Deferred Revenue (Quarter) stood at $639020.9 in 2023, then crashed by 95.64% to $27843.1 in 2024, then soared by 396.54% to $138252.7 in 2025.
  • Its Current Deferred Revenue was $138252.7 in Q2 2025, compared to $27843.1 in Q4 2024 and $639020.9 in Q4 2023.